Abstract
Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have